ATL1102 is an antisense oligonucleotide designed to inhibit CD49d expressed on T cells implicated in the inflammatory/immune response in Duchenne. Inhibition of CD49d aims to decrease the inflammation that accompanies loss of dystrophin in Duchenne.
A phase 2 study is actively recruiting EX-US.
This program is sponsored by Antisense Therapeutics.
ACTIVELY RECRUITING | A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy |
JULY 2020 | Antisense Therapeutics at the PPMD 2020 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library |
